Eisai to Launch Sahne Medical Spray and Sahne Medical Cream

Aug 25, 2020 12:55 JST

Source: Eisai

Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care products

Sahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid

TOKYO, Aug 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched Sahne Medical Spray and Sahne Medical Cream (both are category-2 OTC drugs, "Sahne Medical") on August 25, 2020 at pharmacies and drugstores throughout Japan, as a new product of the Sahne brand lineup which has been a favored hand care for generations.

Eisai conducted a survey of 1,000 women in their 40s to 50s in April 2020. As a result, it was found that approximately 70% of the subjects felt that the dryness of their skin and/or the dry skin expanse had increased compared to its condition five years ago. Additionally, a number of comments regarding the discomfort of dryness from people with dry skin were received as follows: "The dryness has spread to my thighs, shins, sides, and back.", "I'm distracted just by my underwear rubbing against my skin.", and "My dry skin flakes stick inside my clothes whenever I get undressed, which makes me uncomfortable." It is considered that the skin condition of women after their late 30s requires more reliable moisturizing effects of pharmaceuticals, since the amounts of sebum, natural moisturizing factors, and intercellular lipids in the stratum corneum necessary for water retention of the skin decrease.

"Sahne Medical" is a category-2 OTC drug containing the active ingredient "Heparinoid", which exerts a high moisturizing effect against dry skin (xeroderma) that worsens with age. Heparinoid penetrates into the stratum corneum, increases natural moisturizing factors, and restores the structure of intercellular lipids in the stratum corneum to moisturize dry skin.

There are two types of product lines, spray and cream, which can be selected depending on the part of the body where the product is applied and/or the principles of TPO (time, place and occasion). "Sahne Medical Spray" is the first OTC drug spray-type lotion containing Heparinoid. This product is handy for the consumer to use on the back, side and back of thigh, where it is difficult to apply the medicine by themselves, as it features a container that can be sprayed upside down and a fine mist-like lotion. In addition, the tube-type "Sahne Medical Cream" is recommended for relieving unbearable discomfort of dryness upon going out, as it is convenient to carry.

The Sahne brand has continued to be a gentle companion to the daily lives of many people for 66 years since its launch. With the new launch of Sahne Medical, a pharmaceutical product, Eisai is now able to provide a remedy for skin problems that it had not been able to contribute to before. Eisai will further respond to the wishes of consumers who want to be relieved of the discomfort of dry skin, with the moisturizing effect of pharmaceutical care products and the gentle nature of Sahne products.

Contact:

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Related Press Release

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

March 27 2026 19:14 JST

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

March 27 2026 17:19 JST

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026

March 23 2026 10:19 JST

Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)

March 19 2026 09:54 JST

Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation

March 17 2026 18:49 JST

Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration

March 12 2026 16:21 JST

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting

March 11 2026 11:07 JST

WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

March 02 2026 08:49 JST

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy

February 16 2026 13:03 JST

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China

February 10 2026 12:34 JST

More Press release >>

Latest Press Release

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Apr 03, 2026 12:33 JST

Hitachi Rail announces agreement to acquire Clever Devices, marking its growth as a global digital mobility player
Apr 03, 2026 11:09 JST

OMRON Healthcare and UCSF launch AFib trial
Apr 03, 2026 00:00 JST

DENSO and FoodVentures Strengthen Collaboration through Capital Partnership in the Agricultural Sector

Apr 02, 2026 19:56 JST

JRC, SKY Perfect JSAT, and Sharp Collaborate to Promote the Ministry of Defense's Publicly Announced Project "Development and Demonstration of Resiliency Technology for Multi-Orbit Communications Systems" Selected for JRC
Apr 02, 2026 16:01 JST

MHIEC Completes Construction of Nanbu Relay Center for Nagasaki Prefecture's Ken'ou-Kennan Clean Authority
Apr 02, 2026 14:57 JST

Moving Beyond the 'Blockbuster' Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach: Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont
Apr 02, 2026 12:00 JST

Mazda EZ-6/Mazda6e Wins 2026 World Car Design of the Year Award
Apr 02, 2026 11:47 JST

Honda Makes Gachaco a Consolidated Subsidiary by Subscribing to New Shares of Gachaco Issued Through Third-party Allotment

Apr 01, 2026 22:09 JST

DENSO Hosted "DENSO DIALOG DAY 2026", Delivers Mid-Term Management Plan "CORE 2030"
Apr 01, 2026 21:54 JST

MHI President Eisaku Ito Offers Words of Encouragement to New Employees at the Company's 2026 Welcoming Ceremony
Apr 01, 2026 13:35 JST

MHI Completes the Transfer Procedures for its Domestic Onshore Wind Power Business
Apr 01, 2026 13:26 JST

Toyota Motor Corporation aims to join Daimler Truck and Volvo Group as equal shareholder in the fuel cell joint venture cellcentric
Mar 31, 2026 23:39 JST

Honda Announces the Establishment of PathAhead Co., Ltd., a Startup Originated from IGNITION, a Honda New Business Creation Program
Mar 31, 2026 21:58 JST

Hitachi Digital Services Strengthens OT-IT Integration with Manufacturing Operations Management Platform
Mar 31, 2026 19:14 JST

Fujitsu and Osaka University of Health and Sport Sciences partner to innovate sports performance with skeleton recognition AI
Mar 31, 2026 17:42 JST

DOCOMO and SK Telecom Publish White Paper on Requirements for Advancing vRAN and AI-RAN in Mobile Networks
Mar 31, 2026 11:00 JST

NEC Supports Ooredoo Algeria in Modernizing Enterprise Network Security with high-performance next-generation firewalls (NGFW)
Mar 31, 2026 10:50 JST

MOL and Hitachi Launch Initiative to Convert Used Ships into Floating Data Centers
Mar 30, 2026 19:21 JST

Resona Holdings, BrainPad, and Fujitsu sign basic agreement for collaboration to transform financial operations with data and AI and advance next-generation data utilization
Mar 30, 2026 15:55 JST

More Latest Release >>